FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770680923> ?p ?o ?g. }

• W2770680923 endingPage "e0188190" @default.
• W2770680923 startingPage "e0188190" @default.
• W2770680923 abstract "Introduction Prophylactic administration of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NAs) is the standard treatment for controlling hepatitis B virus (HBV) recurrence after liver transplantation (LT). Since lifelong use of HBIG is expensive and inconvenient and the antibodies level in anti-hepatitis B surface (HBs) is not sustainable and stable, an alternative strategy is to produce anti-HBs antibodies by active immunization. Our present study aimed to prospectively investigate the efficacy and safety of procedural HBV vaccination in transplanted patients. Methods Recipients who had undergone LT for hepatitis B related liver diseases more than one year before, with no evidence of HBV recurrence or rejection and normal liver function were enrolled. All subjects received the hepatitis B vaccine (40 μg) by intramuscular injection at months 0, 1, 2, 6 and 12 after enrollment with continuous administration of NAs. The liver function and anti-HBs titers were measured before each vaccination and HBIG (400U) was administrated intramuscularly when anti-HBs titer was lower than 30 IU/L during the course. The results of routine blood tests, liver function, concentration of immunosuppressant, and HBV-DNA copies were monitored during the research. After completion of the vaccination procedure, recipients were regarded as responders if their anti-HBs greater than 30 IU/L were maintained for up to six months without using HBIG and vaccine. Results Twenty-seven patients were enrolled in this study and the average anti-HBs titer before vaccination was 19.86±14.80 IU/L. The average anti-HBs titer of the nine responders at the end of the follow-up was 57.14±22.75 IU/L, giving an overall response rate of 33.3% (9/27). There were no reports of reactivation of HBV, rejection, severe anaphylaxis or other adverse events. Responders and non-responders showed their significant difference in anti-HBs titers after the fourth vaccination (P<0.01). Moreover, the majority of non-responders (11/18, 63.64%) had high LY/EO rates (lymphocyte number/eosinophil number>15) while most responders (8/9, 88.89%) had low LY/EO rates at the beginning of vaccination (P = 0.019). Conclusions Active immunization is an effective, cost-saving, and safe method for the prevention of HBV reactivation in patients transplanted for hepatitis B virus related liver diseases. The LY/EO rate may be a valuable indicator in selecting potential recipients for vaccination." @default.
• W2770680923 created "2017-12-04" @default.
• W2770680923 creator A5013289800 @default.
• W2770680923 creator A5018160861 @default.
• W2770680923 creator A5024094461 @default.
• W2770680923 creator A5029796589 @default.
• W2770680923 creator A5030015618 @default.
• W2770680923 creator A5059629608 @default.
• W2770680923 creator A5061481279 @default.
• W2770680923 creator A5069668962 @default.
• W2770680923 creator A5071358129 @default.
• W2770680923 creator A5082091746 @default.
• W2770680923 creator A5083393257 @default.
• W2770680923 date "2017-11-16" @default.
• W2770680923 modified "2023-10-18" @default.
• W2770680923 title "Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study" @default.
• W2770680923 cites W1037080201 @default.
• W2770680923 cites W1770263627 @default.
• W2770680923 cites W1821077834 @default.
• W2770680923 cites W1870853601 @default.
• W2770680923 cites W1871200309 @default.
• W2770680923 cites W1893558636 @default.
• W2770680923 cites W1945283346 @default.
• W2770680923 cites W1983596272 @default.
• W2770680923 cites W1983634289 @default.
• W2770680923 cites W1998484672 @default.
• W2770680923 cites W2010561209 @default.
• W2770680923 cites W2012621209 @default.
• W2770680923 cites W2021292156 @default.
• W2770680923 cites W2049667588 @default.
• W2770680923 cites W2068915975 @default.
• W2770680923 cites W2070401728 @default.
• W2770680923 cites W2077105448 @default.
• W2770680923 cites W2129955924 @default.
• W2770680923 cites W2135205023 @default.
• W2770680923 cites W2140572565 @default.
• W2770680923 cites W2148193380 @default.
• W2770680923 cites W2166132400 @default.
• W2770680923 cites W2169796429 @default.
• W2770680923 cites W2176143050 @default.
• W2770680923 cites W2258018253 @default.
• W2770680923 cites W2299813105 @default.
• W2770680923 cites W2404084084 @default.
• W2770680923 cites W2417106442 @default.
• W2770680923 cites W2418046349 @default.
• W2770680923 cites W2437872764 @default.
• W2770680923 cites W2471684625 @default.
• W2770680923 doi "https://doi.org/10.1371/journal.pone.0188190" @default.
• W2770680923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5690662" @default.
• W2770680923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29145470" @default.
• W2770680923 hasPublicationYear "2017" @default.
• W2770680923 type Work @default.
• W2770680923 sameAs 2770680923 @default.
• W2770680923 citedByCount "10" @default.
• W2770680923 countsByYear W27706809232019 @default.
• W2770680923 countsByYear W27706809232020 @default.
• W2770680923 countsByYear W27706809232021 @default.
• W2770680923 countsByYear W27706809232023 @default.
• W2770680923 crossrefType "journal-article" @default.
• W2770680923 hasAuthorship W2770680923A5013289800 @default.
• W2770680923 hasAuthorship W2770680923A5018160861 @default.
• W2770680923 hasAuthorship W2770680923A5024094461 @default.
• W2770680923 hasAuthorship W2770680923A5029796589 @default.
• W2770680923 hasAuthorship W2770680923A5030015618 @default.
• W2770680923 hasAuthorship W2770680923A5059629608 @default.
• W2770680923 hasAuthorship W2770680923A5061481279 @default.
• W2770680923 hasAuthorship W2770680923A5069668962 @default.
• W2770680923 hasAuthorship W2770680923A5071358129 @default.
• W2770680923 hasAuthorship W2770680923A5082091746 @default.
• W2770680923 hasAuthorship W2770680923A5083393257 @default.
• W2770680923 hasBestOaLocation W27706809231 @default.
• W2770680923 hasConcept C126322002 @default.
• W2770680923 hasConcept C159654299 @default.
• W2770680923 hasConcept C203014093 @default.
• W2770680923 hasConcept C22070199 @default.
• W2770680923 hasConcept C2522874641 @default.
• W2770680923 hasConcept C2777382497 @default.
• W2770680923 hasConcept C2777410769 @default.
• W2770680923 hasConcept C2779609443 @default.
• W2770680923 hasConcept C2780056496 @default.
• W2770680923 hasConcept C2780593183 @default.
• W2770680923 hasConcept C2780801004 @default.
• W2770680923 hasConcept C2781037505 @default.
• W2770680923 hasConcept C2911091166 @default.
• W2770680923 hasConcept C2992208098 @default.
• W2770680923 hasConcept C32611913 @default.
• W2770680923 hasConcept C71924100 @default.
• W2770680923 hasConcept C90924648 @default.
• W2770680923 hasConceptScore W2770680923C126322002 @default.
• W2770680923 hasConceptScore W2770680923C159654299 @default.
• W2770680923 hasConceptScore W2770680923C203014093 @default.
• W2770680923 hasConceptScore W2770680923C22070199 @default.
• W2770680923 hasConceptScore W2770680923C2522874641 @default.
• W2770680923 hasConceptScore W2770680923C2777382497 @default.
• W2770680923 hasConceptScore W2770680923C2777410769 @default.
• W2770680923 hasConceptScore W2770680923C2779609443 @default.
• W2770680923 hasConceptScore W2770680923C2780056496 @default.
• W2770680923 hasConceptScore W2770680923C2780593183 @default.

• next